#temelimab — Public Fediverse posts

In der Schweiz ist #Geneuro auf der Suche nach #LongCovid-Erkrankten, die an der Therapiestudie mit #Temelimab teilnehmen möchten. Es geht insbesondere um neurologische und psychiatrische Symptome.

https://www.geneuro.com/en/clinicaltrials/german

An alle Post-Covid Betroffenen in der Schweiz (und Umgebung) & deren Angehörige:

In der Schweiz startete eine Studie für ein Medikament gegen Post-Covid. Es werden 200 Patient*innen in fünf verschiedenen Spitälern aufgenommen.

Es hat noch freie Plätze!

#temelimab

1/6

An alle Post-Covid Betroffenen in der Schweiz (und Umgebung) & deren Angehörige:

In der Schweiz startete eine Studie für ein Medikament gegen Post-Covid. Es werden 200 Patient*innen in fünf verschiedenen Spitälern aufgenommen.

Es hat noch freie Plätze!

#temelimab

1/6

RT 🔗🐦

https://twitter.com/anthokhun/status/1595809222838599680?t=78bR_FYzcjSWK6h6oMOR8w&s=19

Very interesting, a participant in the Post-Covid study with #temelimab will tell about his journey with #CovidLong and also talk about the study he is participating in 🇨🇭. Lots of hope for #MultipleSclerosis patients too with this drug candidate 🌞.

https://clinicaltrials.gov/ct2/show/NCT05497089

#MSChat #LongCovid #PostCovid #Temelimab

@SilverGorilla2 🙏
I am not a scientist, I've read that the envelope protein of the #HERV-W #Retrovirus might be an aggravating factor in #MS and that it would also play a role in inflammatory #psychosis, as well as in min. 25% of #longcovid. All this has been published. Forseps.org has been following this trail for 10 years. A P2 trial with #temelimab targeting this protein is recruiting in 🇨🇭 Switzerland. The P2 in #MS had positive results, presented at #ECTRIMS2022#mschat

@SilverGorilla2 🙏
I am not a scientist, I've read that the envelope protein of the #HERV-W #Retrovirus might be an aggravating factor in #MS and that it would also play a role in inflammatory #psychosis, as well as in min. 25% of #longcovid. All this has been published. Forseps.org has been following this trail for 10 years. A P2 trial with #temelimab targeting this protein is recruiting in 🇨🇭 Switzerland. The P2 in #MS had positive results, presented at #ECTRIMS2022#mschat

👉An interesting paper :

"HERV-W ENV antigenemia and correlation of increased anti-SARS-CoV-2 immunoglobulin levels with post-COVID-19 symptoms."

" (...) The present study shows, for the first time, that the HERV-W ENV protein can still be actively expressed long after SARS-CoV-2 infection is resolved in post-COVID-19 condition patients.(...)"

There's a P2 clinical trial enrolling:

https://clinicaltrials.gov/ct2/show/NCT05497089

#Post-Covid #LongCovid #SARS-CoV-2 #Retrovirus #PHERV-W env #Temelimab #ClinicalTrial

👉An interesting paper :

"HERV-W ENV antigenemia and correlation of increased anti-SARS-CoV-2 immunoglobulin levels with post-COVID-19 symptoms."

" (...) The present study shows, for the first time, that the HERV-W ENV protein can still be actively expressed long after SARS-CoV-2 infection is resolved in post-COVID-19 condition patients.(...)"

There's a P2 clinical trial enrolling:

https://clinicaltrials.gov/ct2/show/NCT05497089

#Post-Covid #LongCovid #SARS-CoV-2 #Retrovirus #PHERV-W env #Temelimab #ClinicalTrial

https://youtu.be/R0lngjHsg9o

Very interesting results on neurodegenation of the ProTEct-MS study with #temelimab at 26:55

https://youtu.be/R0lngjHsg9o

Very interesting results on #Neurodegeneration of the ProTEct-#MS study with #temelimab at 26:55